Management of residual mass in nonseminomatous germ cell tumors following chemotherapy

被引：16

作者：

Daneshmand, Siamak ^{[1
]}

Djaladat, Hooman ^{[2
]}

Nichols, Craig ^{[3
]}

机构：

[1] USC, Inst Urol, 1441 East Lake Ave,Suite 7461, Los Angeles, CA 90033 USA

[2] USC, Norris Comprehens Canc Ctr, Inst Urol, Los Angeles, CA USA

[3] Testis Canc Consortium, Portland, OR USA

来源：

THERAPEUTIC ADVANCES IN UROLOGY | 2011年 / 3卷 / 04期

关键词：

chemotherapy; residual mass; testis cancer;

D O I：

10.1177/1756287211418721

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses > 1cm following induction chemotherapy with normalized tumor markers should undergo a postchemotherapy retroperitoneal lymph node dissection. Post chemotherapy retroperitoneal residual mass less than 1 cm with normal markers may be considered as complete response, although the possibility of residual teratoma and viable germ cell tumor are not definitively ruled out. Excellent long term disease free survival following surveillance may justify this option as the treatment of choice in this cohort of patients.

引用

页码：163 / 171

页数：9

共 62 条

[1]

Albers Peter, 2002, Curr Opin Urol, V12, P435, DOI 10.1097/00042307-200209000-00012

[2]

APRIKIAN AG, 1994, CANCER, V74, P1329, DOI 10.1002/1097-0142(19940815)74:4<1329::AID-CNCR2820740424>3.0.CO

[3]

2-L

[4]

Baniel J, 1999, SEMIN SURG ONCOL, V17, P263, DOI 10.1002/(SICI)1098-2388(199912)17:4<263::AID-SSU7>3.0.CO

[5]

2-6

[6]

Basiri A, 2010, UROL J, V7, P157

[7] Tumor marker levels in post-chemotherapy cystic masses: Clinical implications for patients with germ cell tumors [J].

Beck, SDW ;

Patel, MI ;

Sheinfeld, J .

JOURNAL OF UROLOGY, 2004, 171 (01) :168-171

[8] Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer [J].

Beck, SDW ;

Foster, RS ;

Bihrle, R ;

Ulbright, T ;

Koch, MO ;

Wahle, GR ;

Einhorn, LH ;

Donohue, JP .

JOURNAL OF UROLOGY, 2002, 168 (04) :1402-1404

[9] Post chemotherapy RPLND in patients with elevated markers: Current concepts and clinical outcome [J].

Beck, Stephen D. W. ;

Foster, Richard S. ;

Bihrle, Richard ;

Einhorn, Lawrence H. ;

Donohue, John P. .

UROLOGIC CLINICS OF NORTH AMERICA, 2007, 34 (02) :219-+

[10] Management of the post chemotherapy subcentimeter residual mass: the case for observation [J].

Beck, Stephen D. W. ;

Foster, Richard S. .

WORLD JOURNAL OF UROLOGY, 2009, 27 (04) :485-488

← 1 2 3 4 5 6 7 →